Thank you for sharing!

Your article was successfully shared with the contacts you provided.
A box of Zantac tablets. On April 1 health regulators told drugmakers to immediately pull their popular heartburn drugs off the market. AP Photo: Wilfredo Lee A box of Zantac tablets. On April 1 health regulators told drugmakers to immediately pull their popular heartburn drugs off the market. AP Photo: Wilfredo Lee

Attorneys eyeing lawsuits over Zantac may be divided on the significance of the U.S. Food and Drug Administration’s decision calling on drugmakers to pull the heartburn medication from the market, but all agree the move highlights what appears to be a growing unease over the safety of the medication.

On Wednesday, the regulatory body announced it was requesting manufacturers to withdraw all prescription and over-the-counter Zantac from the market over concerns that a potentially carcinogenic molecule in the drug may build up over time if the medication is stored above room temperature. According to a press release issued Wednesday, the move is part of an ongoing investigation into the molecule N-Nitrosodimethylamine, or NDMA, which is a component of the drug.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Max Mitchell

Max Mitchell is ALM's Pennsylvania Bureau Chief overseeing The Legal Intelligencer, Delaware Law Weekly and Delaware Business Court Insider. Follow him on Twitter @MMitchellTLI. His email is [email protected]

More from this author

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.

New Jersey Insurance LawBook

Comprehensive, accurate comprehensive information about insurance policy law, recent statutory requirements, in-depth discussions of key insurance concepts, and a glossa...

Get More Information

America's Claims Executive Virtual Leadership Forum & Expo 2021Event

ACE Virtual Leadership Forum & Expo is the annual conference for Senior Claims Executives in Insurance organizations.

Get More Information

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.